| Literature DB >> 15852254 |
Robert S Wallis1, Stefan Ehlers.
Abstract
Several studies show that the risk of granulomatous infections following therapy with the anti-tumor necrosis factor (TNF) antibody infliximab is higher than after treatment with the soluble TNFRp75 immunoglobulin fusion construct etanercept. Therefore, despite sharing a common target, it is possible that the actual mode of action of the 2 biologicals differs in vivo. TNF is known to participate in the induction and maintenance of protective granulomas at multiple steps, and evidence supporting a differential inhibition of TNF bioactivity and signaling by the 2 drugs is discussed.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15852254 DOI： 10.1016/j.semarthrit.2005.01.009
Source DB: PubMed Journal: Semin Arthritis Rheum ISSN： 0049-0172 Impact factor: 5.532